Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery - Trial NCT05966961
Access comprehensive clinical trial information for NCT05966961 through Pure Global AI's free database. This phase not specified trial is sponsored by Aesculap AG and is currently Not yet recruiting. The study focuses on Surgical Site Infection. Target enrollment is 2998 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Novosyn® in emergency or elective laparotomy or laparoscopic surgery
Observational
device
Sponsor & Location
Aesculap AG
Timeline & Enrollment
N/A
Aug 01, 2023
Aug 01, 2028
Primary Outcome
Frequency of surgical site infection (superficial (A1) and deep (A2)
Summary
The aim of the study is to elucidate, if the colonization of bacteria is lower on the
 Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by
 the incidence of surgical site infections (SSI: A1 and A2). The results of this registry will
 generate further clinical evidence for the use and the benefit of a Chlorhexidine coated
 suture used to close the wound after an emergency or elective laparoscopic or laparotomy
 surgery. The benefit for individual patients lies in the early diagnosis of complications and
 in the optimized postoperative controls of a clinical study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05966961
Device Trial